Vasopressors and inotropes

Paradise Lost and the Cosmological Revolution

Volumn , Issue , 2014, Pages 85-94

  Thiele, Robert H ^a   Isbell, James M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84953400346     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781107257115.012     Document Type: Chapter

References (115)

1. Rudner XL, Berkowitz DE, Booth JV, Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 1999; 100(23): 2336-43.
2. Brodde OE. Physiology and pharmacology of cardiovascular catecholamine receptors: implications for treatment of chronic heart failure. Am Heart J 1990; 120 (6 Pt 2): 1565-72.
3. Hoffbrand BI, Forsyth RP. Regional blood flow changes during norepinephrine, tyramine and methoxamine infusions in the unanesthetized rhesus monkey. J Pharmacol Exp Ther 1973; 184 (3): 656-61.
4. Kaumann AJ, Molenaar P. Modulation of human cardiac function through 4 betaadrenoceptor populations. Naunyn Schmiedebergs Arch Pharmacol 1997; 355(6): 667-81.
5. Bylund DB, Snyder SH. Beta adrenergic receptor binding in membrane preparations from mammalian brain. Mol Pharmacol 1976; 12(4): 568-80.
6. Molinoff PB. Alpha-and betaadrenergic receptor subtypes properties, distribution and regulation. Drugs 1984; 28 Suppl 2: 1-15.
7. Harms HH, Van der Meer J. Isoprenaline antagonism of cardioselective beta-adrenergic receptor blocking agents on human and rat adipocytes. Br J Clin Pharmacol 1975; 2(4): 311-15.
8. White M, Yanowitz F, Gilbert EM, Role of beta-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 1995; 76(17): 1271-6.
9. Davis C, Conolly ME, Greenacre JK. Beta-adrenoceptors in human lung, bronchus and lymphocytes. Br J Clin Pharmacol 1980; 10 (5): 425-432.
10. Harms HH. Isoproterenol antagonism of cardioselective beta adrenergic receptor blocking agents: a comparative study of human and guinea-pig cardiac and bronchial beta adrenergic receptors. J Pharmacol Exp Ther 1976; 199(2): 329-35.
11. Koch-Weser J, Frishman WH. beta-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med 1981; 305(9): 500-6.
12. Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG, Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967; 214(5088): 597-8.
13. Dunlop D, Shanks RG. Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother 1968; 32 (1): 201-18.
14. Michel MC, Brodde OE, Insel PA. Peripheral adrenergic receptors in hypertension. Hypertension 1990; 16(2): 107-20.
15. Koshimizu TA, Nakamura K, Egashira N, Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev 2012; 92 (4): 1813-64.
16. Morel A, O'Carroll AM, Brownstein MJ, Lolait SJ. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 1992; 356 (6369): 523-6.
17. Sugimoto T, Saito M, Mochizuki S, Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem 1994; 269 (43): 27088-92.
18. Lolait SJ, O'Carroll AM, McBride OW, Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 1992; 357 (6376): 336-9.
19. Birnbaumer M, Seibold A, Gilbert S, Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992; 357 (6376): 333-5.
20. Bichet DG, Razi M, Lonergan M, Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 1988; 318 (14): 881-7.
21. Haslam RJ, Rosson GM. Effect of vasopressin on human blood platelets. J Physiol 1971; 219 (2): 36P-8P. 22. Haslam RJ, Rosson GM. Aggregation of human blood platelets by vasopressin. Am J Physiol 1972; 223(4): 958-67.
22. Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand's disease. Br J Haematol 1981; 47(2): 283-93.
23. Hardman JG. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 9th edn. New York: McGraw-Hill, 1996.
24. Schwinn DA, Reves JG. Time course and hemodynamic effects of alpha-1-adrenergic bolus administration in anesthetized patients with myocardial disease. Anesth Analg 1989; 68 (5): 571-8.
25. Craig CR, Stitzel RE. Modern Pharmacology With Clinical Applications. Vol 6th: Lippincott Williams & Wilkins, 2003.
26. Treschan TA, Peters J. The vasopressin system: physiology and clinical strategies. Anesthesiology. 2006; 105 (3): 599-612; quiz 639-40.
27. Rehberg S, Ertmer C, Lange M, Role of selective V2-receptor-antagonism in septic shock: a randomized, controlled, experimental study. Crit Care 2010; 14(6): R200.
28. Baumann G, Dingman JF. Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest 1976; 57(5): 1109-16.
29. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest 2001; 120(3): 989-1002.
30. Goldberg LI. Dopamine - clinical uses of an endogenouscatecholamine. N Engl J Med 1974; 291(14): 707-10.
31. Goldberg LI. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 1972; 24(1): 1-29.
32. Marino RJ, Romagnoli A, Keats AS. Selective venoconstriction by dopamine in comparison with isoproterenol and phenylephrine. Anesthesiology 1975; 43(5): 570-2.
33. Overgaard CB, Dzavik V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation 2008; 118 (10): 1047-56.
34. Gillespie TA, Ambos HD, Sobel BE, Roberts R. Effects of dobutamine in patients with acute myocardial infarction. Am J Cardiol 1977; 39(4): 588-94.
35. Robie NW, Nutter DO, Moody C, McNay JL. In vivo analysis of adrenergic receptor activity of dobutamine. Circ Res 1974; 34 (5): 663-71.
36. De Backer D, Zhang H, Manikis P, Vincent JL. Regional effects of dobutamine in endotoxic shock. J Surg Res 1996; 65(2): 93-100.
37. Tuttle RR, Mills J. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res 1975; 36(1): 185-96.
38. Ruffolo RR, Jr., Yaden EL. Vascular effects of the stereoisomers of dobutamine. J Pharmacol Exp Ther 1983; 224 (1): 46-50.
39. Appleton C, Olajos M, Morkin E, Goldman S. Alpha-1 adrenergic control of the venous circulation in intact dogs. J Pharmacol Exp Ther 1985; 233 (3): 729-34.
40. Eichler HG, Ford GA, Blaschke TF, Swislocki A, Hoffman BB. Responsiveness of superficial hand veins to phenylephrine in essential hypertension. Alpha adrenergic blockade during prazosin therapy. J Clin Invest 1989; 83(1): 108-12.
41. Hirakawa S, Itoh H, Kotoo Y, The role of alpha and beta adrenergic receptors in constriction and dilation of the systemic capacitance vessels: a study with measurements of the mean circulatory pressure in dogs. Jpn Circ J 1984; 48(7): 620-32.
42. Pang CC. Autonomic control of the venous system in health and disease: effects of drugs. Pharmacol Ther 2001; 90 (2-3): 179-230.
43. Tuman KJ, McCarthy RJ, March RJ, Guynn TP, Ivankovich AD. Effects of phenylephrine or volume loading on right ventricular function in patients undergoing myocardial revascularization. J Cardiothorac Vasc Anesth 1995; 9 (1): 2-8.
44. Landzberg JS, Parker JD, Gauthier DF, Colucci WS. Effects of myocardial alpha 1-adrenergic receptor stimulation and blockade on contractility in humans. Circulation 1991; 84 (4): 1608-14.
45. Lang RM, Borow KM, Neumann A, Janzen D. Systemic vascular resistance: an unreliable index of left ventricular afterload. Circulation 1986; 74(5): 1114-23.
46. Heyndrickx GR, Boettcher DH, Vatner SF. Effects of angiotensin, vasopressin, and methoxamine on cardiac function and blood flow distribution in conscious dogs. Am J Physiol 1976; 231 (5 Pt. 1): 1579-87.
47. Woodman OL, Vatner SF. Coronary vasoconstriction mediated by alpha 1-and alpha 2-adrenoceptors in conscious dogs. Am J Physiol 1987; 253 (2 Pt 2): H388-93.
48. Crystal GJ, Kim SJ, Salem MM, Abdel-Latif M. Myocardial oxygen supply/demand relations during phenylephrine infusions in dogs. Anesth Analg 1991; 73(3): 283-8.
49. Loeb HS, Saudye A, Croke RP, Effects of pharmacologicallyinduced hypertension on myocardial ischemia and coronary hemodynamics in patients with fixed coronary obstruction. Circulation 1978; 57 (1): 41-6.
50. Smith JS, Roizen MF, Cahalan MK, Does anesthetic technique make a difference? Augmentation of systolic blood pressure during carotid endarterectomy: effects of phenylephrine versus light anesthesia and of isoflurane versus halothane on the incidence of myocardial ischemia. Anesthesiology 1988; 69(6): 846-53.
51. Gelman S, Mushlin PS. Catecholamine-induced changes in the splanchnic circulation affecting systemic hemodynamics. Anesthesiology 2004; 100(2): 434-9.
52. Zandberg P, Timmermans PB, van Zwieten PA. Hemodynamic profiles of methoxamine and B-HT 933 in spinalized ganglionblocked dogs. J Cardiovasc Pharmacol 1984; 6(2): 256-62.
53. Langesaeter E, Rosseland LA, Stubhaug A. Continuous invasive blood pressure and cardiac output monitoring during cesarean delivery: a randomized, double-blind comparison of low-dose versus high-dose spinal anesthesia with intravenous phenylephrine or placebo infusion. Anesthesiology 2008; 109(5): 856-63.
54. Stewart A, Fernando R, McDonald S, The dosedependent effects of phenylephrine for elective cesarean delivery under spinal anesthesia. Anesth Analg 2010; 111 (5): 1230-7.
55. Grangsjo G, Persson E. Influence of some vaso-active substances on regional blood flow in the dog kidney. A study on normovolaemic and hypovolaemic dogs. ActaAnaesthesiol Scand 1971; 15 (2): 71-95.
56. Liard JF, Deriaz O, Schelling P, Thibonnier M. Cardiac output distribution during vasopressin infusion or dehydration in conscious dogs. Am J Physiol 1982; 243(5): H663-9.
57. Ericsson BF. Effect of vasopressin on the distribution of cardiac output and organ blood flow in the anesthetized dog. Acta Chir Scand 1971; 137(8): 729-38.
58. Schmid PG, Abboud FM, Wendling MG, Regional vascular effects of vasopressin: plasma levels and circulatory responses. Am J Physiol 1974; 227 (5): 998-1004.
59. Michel JB, Tedgui A, Bardou A, Levy B. Effect of vasopressin on phasic coronary blood flow. Basic Res Cardiol. 1985; 80(3): 221-30.
60. Pantely GA, Ladley HD, Anselone CG, Bristow JD. Vasopressininduced coronary constriction at low perfusion pressures. Cardiovasc Res 1985; 19 (7): 433-41.
61. Martin DS, McNeill JR. Sensitivity of intestinal resistance vessels to vasopressin after ganglionic blockade in the conscious cat. J Cardiovasc Pharmacol 1987; 9 (3): 368-74.
62. Hofbauer KG, Studer W, Mah SC, The significance of vasopressin as a pressor agent. J Cardiovasc Pharmacol 1984; 6 Suppl 2: S429-38.
63. Kerr JC, Hobson RW, 2nd, Seelig RF, Swan KG. Influence of vasopressin on colon blood flow in monkeys. Gastroenterology 1977; 72(3): 474-8.
64. Hammer M, Skagen K. Effects of small changes of plasma vasopressin on subcutaneous and skeletal muscle blood flow in man. Acta Physiol Scand 1986; 127 (1): 67-73.
65. Erwald R, Wiechel KL, Strandell T. Effect of vasopressin on regional splanchnic blood flows in conscious man. Acta Chir Scand 1976; 142(1): 36-42.
66. Okamura T, Ayajiki K, Fujioka H, Toda N. Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries. J Hypertens 1999; 17(5): 673-8.
67. Katusic ZS, Shepherd JT, Vanhoutte PM. Vasopressin causes endothelium-dependent relaxations of the canine basilar artery. Circ Res 1984; 55(5): 575-9.
68. Vanhoutte PM, Katusic ZS, Shepherd JT. Vasopressin induces endothelium-dependent relaxations of cerebral and coronary, but not of systemic arteries. J Hypertens Suppl 1984; 2 (3): S421-2.
69. Tribollet E, Barberis C, Jard S, Dubois-Dauphin M, Dreifuss JJ. Localization and pharmacological characterization of high affinity binding sites for vasopressin and oxytocin in the rat brain by light microscopic autoradiography. Brain Res 1988; 442(1): 105-18.
70. Phillips PA, Abrahams JM, Kelly J, Localization of vasopressin binding sites in rat brain by in vitro autoradiography using a radioiodinated V1 receptor antagonist. Neuroscience 1988; 27 (3): 749-61.
71. Ostrowski NL, Lolait SJ, Bradley DJ, Distribution of V1a and V2 vasopressin receptor messenger ribonucleic acids in rat liver, kidney, pituitary and brain. Endocrinology 1992; 131(1): 533-5.
72. Lassoff S, Altura BM. Do pial terminal arterioles respond to local perivascular application of the neurohypophyseal peptide hormones, vasopressin and oxytocin? Brain Res 1980; 196 (1): 266-9.
73. Walker BR, Haynes J, Jr., Wang HL, Voelkel NF. Vasopressininduced pulmonary vasodilation in rats. Am J Physiol 1989; 257 (2 Pt 2): H415-22.
74. Wallace AW, Tunin CM, Shoukas AA. Effects of vasopressin on pulmonary and systemic vascular mechanics. Am J Physiol 1989; 257 (4 Pt 2): H1228-34.
75. Jeon Y, Ryu JH, Lim YJ, Comparative hemodynamic effects of vasopressin and norepinephrine after milrinoneinduced hypotension in off-pump coronary artery bypass surgical patients. Eur J Cardiothorac Surg 2006; 29(6): 952-6.
76. Landry DW, Levin HR, Gallant EM, Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997; 25(8): 1279-82.
77. Eisenman A, Armali Z, Enat R, Bankir L, Baruch Y. Low-dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure. J Intern Med 1999; 246(2): 183-90.
78. Gold J, Cullinane S, Chen J, Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure. Am J Cardiol 2000; 85(4): 506-8.
79. Edwards RM, Trizna W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 1989; 256(2 Pt 2): F274-8.
80. McVicar AJ. Dose-response effects of pressor doses of arginine vasopressin on renal haemodynamics in the rat. J Physiol 1988; 404: 535-46.
81. Harrison-Bernard LM, Carmines PK. Juxtamedullary microvascular responses to arginine vasopressin in rat kidney. Am J Physiol 1994; 267(2 Pt 2): F249-56.
82. Braunwald E, Wagner HN, Jr. The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. J Clin Invest 1956; 35(12): 1412-18.
83. Tsuneyoshi I, Yamada H, Kakihana Y, Hemodynamic and metabolic effects of low-dosevasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29(3): 487-93.
84. Cowley AW, Jr., Monos E, Guyton AC. Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res 1974; 34(4): 505-14.
85. Share L. Role of vasopressin in cardiovascular regulation. Physiol Rev 1988; 68(4): 1248-84.
86. Williams TD, Da Costa D, Mathias CJ, Bannister R, Lightman SL. Pressor effect of arginine vasopressin in progressive autonomic failure. Clin Sci (Lond) 1986; 71 (2): 173-8.
87. Bussien JP, Waeber B, Nussberger J, Does vasopressin sustain blood pressure of normally hydrated healthy volunteers? Am J Physiol 1984; 246(1 Pt 2): H143-7.
88. Goldsmith SR, Francis GS, Cowley AW, Cohn JN. Response of vasopressin and norepinephrine to lower body negative pressure in humans. Am J Physiol 1982; 243(6): H970-3.
89. Goldsmith SR. Baroreceptormediated suppression of osmotically stimulated vasopressin in normal humans. J Appl Physiol 1988; 65(3): 1226-30.
90. Jordan J, Tank J, Diedrich A, Robertson D, Shannon JR. Vasopressin and blood pressure in humans. Hypertension 2000; 36(6): E3-4.
91. Kaufmann H, Oribe E, Miller M, Hypotension-induced vasopressin release distinguishes between pure autonomic failure and multiple system atrophy with autonomic failure. Neurology 1992; 42(3 Pt 1): 590-3.
92. Zerbe RL, Henry DP, Robertson GL. Vasopressin response to orthostatic hypotension. Etiologic and clinical implications. Am J Med 1983; 74(2): 265-71.
93. Leimbach WN, Jr., Schmid PG, Mark AL. Baroreflex control of plasma arginine vasopressin in humans. Am J Physiol 1984; 247 (4 Pt 2): H638-44.
94. Argenta LC, Kirsh MM, Bove EL, A comparison of the hemodynamic effects of inotropic agents. Ann Thorac Surg 1976; 22 (1): 50-7.
95. Horwitz D, Fox Sm D, Goldberg LI. Effects of dopamine in man. Circ Res 1962; 10: 237-43.
96. McDonald RH, Jr., Goldberg LI, McNay JL, Tuttle EP, Effect of dopamine in man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. J Clin Invest 1964; 43: 1116-24.
97. Maestracci P, Grimaud D, Livrelli N, Philip F, Dolisi C. Increase in hepatic blood flow and cardiac output during dopamine infusion in man. Crit Care Med 1981; 9 (1): 14-16.
98. Sato Y, Matsuzawa H, Eguchi S. Comparative study of effects of adrenaline, dobutamine and dopamine on systemic hemodynamics and renal blood flow in patients following open heart surgery. Jpn Circ J 1982; 46 (10): 1059-72.
99. Carroll JD, Lang RM, Neumann AL, Borow KM, Rajfer SI. The differential effects of positive inotropic and vasodilator therapy on diastolic properties in patients with congestive cardiomyopathy. Circulation 1986; 74(4): 815-25.
100. Johnston AJ, Steiner LA, O'Connell M, Pharmacokinetics and pharmacodynamics of dopamine and norepinephrine in critically ill head-injured patients. Intens Care Med 2004; 30(1): 45-50.
101. Vatner SF, Higgins CB, Braunwald E. Effects of norepinephrine on coronary circulation and left ventricular dynamics in the conscious dog. Circ Res 1974; 34(6): 812-23.
102. Goertz AW, Lindner KH, Seefelder C, Effect of phenylephrine bolus administration on global left ventricular function in patients with coronary artery disease and patients with valvular aortic stenosis. Anesthesiology 1993; 78 (5): 834-41.
103. Goertz AW, Schmidt M, Seefelder C, Lindner KH, Georgieff M. The effect of phenylephrine bolus administration on left ventricular function during isofluraneinduced hypotension. Anesth Analg 1993; 77(2): 227-31.
104. Fowler NO, Westcott RN, Scott RC, Mc GJ. The effect of norepinephrine upon pulmonary arteriolar resistance in man. J Clin Invest 1951; 30(5): 517-24.
105. King BD, Sokoloff L, Wechsler RL. The effects of l-epinephrine and l-norepinephrine upon cerebral circulation and metabolism in man. J Clin Invest 1952; 31(3): 273-9.
106. Sensenbach W, Madison L, Ochs L. A comparison of the effects of 1-norepinephrine, synthetic 1-epinephrine, and U.S.P. epinephrine upon cerebral blood flow and metabolism in man. J Clin Invest 1953; 32(3): 226-32.
107. Sharrock NE, Go G, Mineo R, Harpel PC. The hemodynamic and fibrinolytic response to low dose epinephrine and phenylephrine infusions during total hip replacement under epidural anesthesia. Thromb Haemost 1992; 68(4): 436-41.
108. Brooker RF, Butterworth JF, 4th, Kitzman DW, Treatment of hypotension after hyperbaric tetracaine spinal anesthesia. A randomized, double-blind, cross-over comparison of phenylephrine and epinephrine. Anesthesiology 1997; 86 (4): 797-805.
109. Rosenblum R, Berkowitz WD, Lawson D. Effect of acute intravenous administration ofisoproterenol on cardiorenal hemodynamics in man. Circulation 1968; 38(1): 158-68.
110. Renard M, Bernard R. Clinical and hemodynamic effects of dobutamine in acute myocardial infarction with left heart failure. J Cardiovasc Pharmacol 1980; 2 (5): 543-52.
111. Ruffolo RR, Jr. The pharmacology of dobutamine. Am J Med Sci 1987; 294(4): 244-8.
112. Akhtar N, Mikulic E, Cohn JN, Chaudhry MH. Hemodynamic effect of dobutamine in patients with severe heart failure. Am J Cardiol 1975; 36(2): 202-5.
113. Leier CV, Webel J, Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation 1977; 56(3): 468-72.
114. Sonnenblick EH, Frishman WH, LeJemtel TH. Dobutamine: a new synthetic cardioactive sympathetic amine. N Engl J Med 1979; 300 (1): 17-22.
115. Ukkonen H, Saraste M, Akkila J, Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997; 61 (5): 596-607.